David Altarac
Dr. David Altarac serves as the chief medical officer at Innoviva Specialty Therapeutics, where he contributed to the development of zoliflodacin, a new antibiotic approved for treating gonorrhea, helping to address the growing issue of antibiotic resistance.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United States | 1 | 9.00 | 0.04% | +0% | 331,002,651 | 148,033 | $21,000,000 | 9,392$ |
| Totals | 1 | 331,002,651 | 148,033 | $21,000,000 | 9,392$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
Dr. David Altarac, chief medical officer at Innoviva Specialty Therapeutics, discussed the potential of zoliflodacin to strengthen treatment options against gonorrhea.
9